Machine Learning and Artificial Intelligence in Pharmaceutical Research and Development: a Review.

Authors:
Kolluri S; Lin J; Liu R; Zhang Y; Zhang W.

Journal:
AAPS J

Publication Year: 2022

DOI:
10.1208/s12248-021-00644-3

PMCID:
PMC8726514

PMID:
34984579

View on PubMed View on PMC View Publisher
Journal Information

Full Title: AAPS J

Abbreviation: AAPS J

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Drug Therapy

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Evaluation of Cellular Immune Response to Adeno-Associated Virus-Based Gene Therapy.
Gorovits B; Azadeh M; Buchlis G and 12 more (2023) - Transparency Score: 3/6
Gastrointestinal Delivery of an mRNA Vaccine Using Immunostimulatory Polymeric Nanoparticles.
Kim H; Kirtane AR; Kim NY and 6 more (2023) - Transparency Score: 3/6
Lessons from CDER's Quality Management Maturity Pilot Programs.
Maguire J; Fisher A; Harouaka D and 9 more (2023) - Transparency Score: 2/6
Leveraging Prior Healthy Participant Pharmacokinetic Data to Evaluate the Impact of Renal and Hepat…
Purohit V; Huh Y; Wojciechowski J and 5 more (2023) - Transparency Score: 4/6
Benchmarking the Quality Practices of Global Pharmaceutical Manufacturing to Advance Supply Chain R…
Fellows M; Friedli T; Li Y and 8 more (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Conflict of InterestSheela K. was previously employed by Takeda Pharmaceuticals and is currently employed by Teva Pharmaceuticals (West Chester PA USA) during the development and revision of this manuscript. All other authors are employed by Takeda Pharmaceuticals during the development and revision of this manuscript. Conflict of Interest Sheela K. was previously employed by Takeda Pharmaceuticals and is currently employed by Teva Pharmaceuticals (West Chester PA USA) during the development and revision of this manuscript. All other authors are employed by Takeda Pharmaceuticals during the development and revision of this manuscript."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025